[Meta] proposal — a flair for phase 2 posts
proposal — a flair for phase 2 posts. Disagreement welcome, but bring a concrete alternative wording.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
I will update this if the picture changes rather than quietly leaving it up.
best — the order this archive was captured in
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
Not convinced. You are attributing a week of fatigue to the glucagon arm when the escalation rate alone would explain it.
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
small trial, big effect, wide error bars
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
phase 2 data only, and people quote it like it is a label
Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.
research-use-only material is not approved for human use, full stop
- 1small trial, big effect, wide error bars6 comments in this branch · started by u/ismael_eriksen